Lignes directrices de pratique clinique 2008 de l - Canadian ...

S166 | Lignes directrices de pratique cLinique 2008
of hypogonadotropic hypogonadism in type 2 diabetes. J Clin
Endocrinol Metab. 2004;89:5462-5468.
23. Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation
in men with type 2 diabetes, visceral obesity and partial
androgen deficiency. Aging Male. 2003;6:1-7.
24. Shabsigh R, Rajfer J, Aversa A, et al. The evolving role of testosterone
in the treatment of erectile dysfunction. Int J Clin Pract.
2006;60:1087-1092.
25. Shabsigh R, Kaufman JM, Steidle C, et al. Randomized study of
testosterone gel as adjunctive therapy to sildenafil in hypogonadal
men with erectile dysfunction who do not respond to sildenafil
alone. J Urol. 2004;172:658-663.
26. Kalinchenko SY, Kozlov GI, Gontcharov NP, et al. Oral testosterone
undecanoate reverses erectile dysfunction associated with
diabetes mellitus in patients failing on sildenafil citrate therapy
alone. Aging Male. 2003;6:94-99.
27. Rosen RC, Riley A, Wagner G, et al. The International Index of
Erectile Function (IIEF): a multidimensional scale for assessment
of erectile dysfunction. Urology. 1997;49:822-830.
28. Cappelleri JC, Rosen RC, Smith MD, et al. Diagnostic evaluation
of the erectile function domain of the International Index
of Erectile Function. Urology. 1999;54:346-351.
29. Ramanathan R, Mulhall J, Rao S, et al. Prospective correlation
between the International Index of Erectile Function
(IIEF) and Sexual Health Inventory for Men (SHIM): implications
for calculating a derived SHIM for clinical use. J Sex Med.
2007;4:1334-1344.
30. Valiquette L, Montorsi F, Auerbach S; Vardenafil Study Group.
First-dose success with vardenafil in men with erectile dysfunction
and associated comorbidities: RELY-I. Int J Clin Pract. 2006;
60:1378-1385.
31. The Diabetes Control and Complications Trial Research Group.
The effect of intensive diabetes therapy on the development and
progression of neuropathy. Ann Intern Med. 1995;122:561-568.
32. The Diabetes Control and Complications Trial Research Group.
The effect of intensive treatment of diabetes on the development
and progression of long-term complications in insulin-dependent
diabetes mellitus. N Engl J Med. 1993;329:977-986.
33. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose
control with sulphonylureas or insulin compared with
conventional treatment and risk of complications in patients
with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
34. Azad N, Emanuele NV, Abraira C, et al. The effects of intensive
glycemic control on neuropathy in the VA Cooperative Study on
Type II Diabetes Mellitus (VA CSDM). J Diabetes Complications.
1990;13:307-313.
35. El-Sakka AI, Hassoba HM, Sayed HM, et al. Pattern of endocrinal
changes in patients with sexual dysfunction. J Sex Med.
2005;2:551-558.
36. Fonseca V, Seftel A, Denne J, et al. Impact of diabetes mellitus
on the severity of erectile dysfunction and response to treatment:
analysis of data from tadalafil clinical trials. Diabetologia.
2004;47:1914-1923.
37. Rendell MS, Rajfer J, Wicker PA, et al. Sildenafil for treatment
of erectile dysfunction in men with diabetes: a randomized controlled
trial. JAMA. 1999;281:421-426.
38. Boulton AJM, Selam J-L, Sweeney M, et al. Sildenafil citrate for
the treatment of erectile dysfunction in men with type II diabetes
mellitus. Diabetologia. 2001;44:1296-1301.
39. Goldstein I, Young JM, Fischer J, et al. Vardenafil, a new phosphodiesterase
type 5 inhibitor, in the treatment of erectile dysfunction
in men with diabetes: a multicenter double-blind placebo-controlled
fixed-dose study. Diabetes Care. 2003;26:777-783.
40. Sáenz de Tejada I, Anglin G, Knight JR, et al. Effects of tadalafil
on erectile dysfunction in men with diabetes. Diabetes Care.
2002;25:2159-2164.
41. Carson CC, Lue TF. Phosphodiesterase type 5 inhibitors for erectile
dysfunction. BJU Int. 2005;96:257-280.
42. Briganti A, Salonia A, Gallina A, et al. Drug insight: oral phosphodiesterase
type 5 inhibitors for erectile dysfunction. Nat Clin
Pract Urol. 2005;2:239-247.
43. DeBusk R, Drory Y, Goldstein I, et al. Management of sexual
dysfunction in patients with cardiovascular disease: recommendations
of the Princeton Consensus Panel. Am J Cardiol. 2000;86:
175-181.
44. Herschorn S. Cardiovascular safety of PDE5 inhibitors. Can J
Urol. 2003;10(suppl 1):23-28.
45. Carson CC, Mulcahy JJ, Govier FE. Efficacy, safety and patient
satisfaction outcomes of the AMS 700CX inflatable penile prosthesis:
results of a long-term multicenter study. J Urol. 2000;164:
376-380.